• SN-38 Disrupts FUBP1–FUSE Binding: Dual Mechanism in Cancer

  2026-06-03

  The referenced study reveals that camptothecin and its analog SN-38, the active metabolite of irinotecan, directly inhibit the binding of the transcriptional regulator FUBP1 to its DNA target sequence FUSE. This dual mechanism—combining DNA topoisomerase I inhibition with interference in oncogenic transcriptional machinery—has significant implications for advanced colon and hepatocellular carcinoma research.

• CPI-613: Applied Strategies for Tumor Cell Metabolism Studie

  2026-06-03

  CPI-613 (6,8-bis(benzylsulfanyl)octanoic acid) uniquely targets mitochondrial metabolism, enabling precise interrogation of PDH- and KGDH-driven pathways in cancer models. This guide connects experimental workflows, troubleshooting, and translational innovations for apoptosis assays and tumor metabolism studies using APExBIO’s validated CPI-613.

• NLRP10 Preserves Epidermal Homeostasis and Barrier in Atopic

  2026-06-02

  This study uncovers NLRP10 as a central regulator of epidermal homeostasis, demonstrating its essential roles in keratinocyte survival, differentiation, and skin barrier integrity in atopic dermatitis (AD). The findings clarify genetic links between NLRP10 and AD, highlighting new mechanistic insights that may inform therapeutic development.

• Blocking GCLC Truncation Delays Cataract Onset by Preserving

  2026-06-02

  Wei et al. (2024) reveal that age-related truncation of the GCLC enzyme critically reduces glutathione (GSH) in the lens, accelerating cataract formation. Preventing this truncation in a knock-in mouse model maintains GSH levels and significantly delays cataracts, offering new insights for age-related ocular disease intervention strategies.

• Necrostatin-1: Redefining RIP1 Inhibition for Translational

  2026-06-01

  Necrostatin-1 (Nec-1) is reshaping the translational landscape by enabling precise RIP1 kinase inhibition, vital for dissecting necroptosis in inflammation and tissue injury. This thought-leadership article equips translational researchers with mechanistic insights, evidence-based experimental guidance, and a strategic vision for leveraging Nec-1 in next-generation disease models, including emerging intersections with gut microbiota-driven inflammation and biomarker discovery.

• QX77: Redefining Chaperone-Mediated Autophagy for Translatio

  2026-06-01

  Explore how QX77, a molecular chaperone activator from APExBIO, empowers translational researchers to modulate chaperone-mediated autophagy with precision. This article bridges mechanistic insight, competitive landscape analysis, and strategic workflow guidance to unlock new advances in stem cell biology and disease modeling.

• FerroOrange Fe²⁺ Fluorescent Probe: Precision Live Cell Iron

  2026-05-31

  FerroOrange sets a new standard for live-cell Fe²⁺ detection, enabling high-sensitivity, real-time monitoring of intracellular iron with minimal background. Its unique selectivity empowers researchers investigating ferroptosis and iron metabolism to achieve reproducible results, particularly in neurobiology and ischemic injury models.

• Microglial Activation and Neuronal Dysregulation in Alcohol-

  2026-05-30

  This study uncovers how acute alcohol exposure triggers microglial activation in the hippocampus, leading to neuronal circuit dysregulation and enhanced seizure susceptibility. By dissecting the interplay between inhibitory and excitatory synapse formation, the research provides a mechanistic basis for neuroimmune contributions to alcohol-induced epilepsy.

• Rapamycin (Sirolimus): Beyond mTOR—Autophagy, Neuroinflammat

  2026-05-29

  Explore the multifaceted roles of Rapamycin (Sirolimus) as a precise mTOR inhibitor, delving into its advanced applications in autophagy and neuroinflammation research. This cornerstone article uniquely bridges cancer, immunology, and neuropathic pain models, offering practical assay guidance and new perspectives beyond standard workflows.

• Isochlorogenic Acid A Modulates HBV via HO-1-Mediated ROS Pa

  2026-05-29

  This study demonstrates that isochlorogenic acid A disrupts hepatitis B virus replication through upregulation of heme oxygenase-1 (HO-1) and altered intracellular ROS, impairing several stages of the viral life cycle. The findings highlight the mechanistic role of HO-1/ROS modulation in antiviral strategies and offer a basis for future metabolic disease and viral research.

• FOXO3 as a Dual Metabolic Regulator in Hepatocellular Carcin

  2026-05-28

  This study uncovers FOXO3 as a pivotal tumor suppressor in hepatocellular carcinoma (HCC) by demonstrating its capacity to coordinately inhibit glycolysis and glutaminolysis through direct repression of YAP transcription. Targeting the FOXO3/YAP axis emerges as a promising metabolic intervention strategy for HCC, with implications for the rational design of combined metabolic therapies.

• 7-Ethyl-10-hydroxycamptothecin: Dual-Action Insights for Col

  2026-05-28

  This article explores how 7-Ethyl-10-hydroxycamptothecin (SN-38) advances translational colon cancer research by targeting both DNA topoisomerase I and the FUBP1–FUSE axis. Integrating mechanistic findings, experimental considerations, and strategic guidance, we highlight new opportunities for researchers and position APExBIO’s product as a precision tool for next-generation studies.

• Optimizing Dye Selection for Small Biopsy Visibility in Hist

  2026-05-27

  This article reviews a 2023 study evaluating dye models to improve the observability of small tissue biopsies during surgical pathology processing. The findings highlight hematoxylin as a low-toxicity, non-interfering tissue marking dye, with implications for workflow optimization and histological staining assay reliability.

• VX-702: Precision p38α MAPK Inhibitor for Inflammation Resea

  2026-05-27

  VX-702 enables selective, high-affinity inhibition of p38α MAPK, offering robust suppression of pro-inflammatory cytokines in both in vitro and in vivo models. Its unique dual-action mechanism and superior selectivity make it a benchmark tool for dissecting inflammatory signaling and optimizing disease models in translational research.

• SB743921: Precision Guide to Kinesin Spindle Protein Inhibit

  2026-05-26

  SB743921 is a potent kinesin spindle protein inhibitor, enabling high-precision studies of mitotic arrest and apoptosis across a spectrum of cancer models. This article translates recent systems-level findings into actionable protocols and troubleshooting strategies, maximizing SB743921’s impact in both standard and advanced cancer research assays.

16680 records 1/1112 page Next 12345 下5页 Last page